A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first­line induction chemotherapy in extensive­ stage small cell lung cancer

Background The 5-year survival rate for extensive-disease small-cell lung carcinoma (ED-SCLC) is only 1%. Recently, apatinib exerted promising effects on cancer patients after failure of first-line chemotherapy. Methods This study enrolled 24 ED-SCLC patients to study the efficacy and toxicity of ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Hao, Zhang, Liang, Yang, Bo, Feng, Yan, Xiong, Yanli, Zhang, Shiheng, Li, Xuemei, Qian, Chengyuan, Dong, Wang, Dai, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985106/
https://www.ncbi.nlm.nih.gov/pubmed/31399906
http://dx.doi.org/10.1007/s10637-019-00828-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985106/
https://www.ncbi.nlm.nih.gov/pubmed/31399906
http://dx.doi.org/10.1007/s10637-019-00828-x

Ejemplares similares